Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 15, 2003Clinical Infectious Diseases

Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMary C. BirminghamJanssen (United States)CRCraig R. RaynerMonash UniversityAMAlison MeagherRoswell Park Comprehensive Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Birmingham et al. (2003) studied this question.

synapsesocial.com/papers/6a6f6fe3e5469ee92be06238https://doi.org/10.1086/345744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Emergence of Vancomycin Resistance inStaphylococcus aureus1999 · 1,092 citations
  2. 2Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration with Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorphan HBr2001 · 85 citations
  3. 3Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial2001 · 129 citations
  4. 4Hematologic Effects of Linezolid: Summary of Clinical Experience2002 · 447 citations